GH Research says H1 loss widens as R&D spending rises on GH001 clinical, technical development work
GHRS•R&D and G&A expenses rise
- R&D expense rose to USD 24.78 million from USD 16.81 million, led by technical and clinical development spending, including trial costs.
- G&A expense increased to USD 13.43 million from USD 10.63 million, mainly reflecting higher professional fees.
H1 loss widens on higher operating costs
GH Research posted a net loss of USD 34.11 million for the six months ended June 30, 2026, driven by higher operating costs.
Finance income falls as cash balance increases
Net finance income fell to USD 4.69 million from USD 5.48 million due to lower investment returns.
Cash, cash equivalents and marketable securities totaled USD 362.7 million, up from USD 280.7 million, supported by USD 111.2 million net equity-offering proceeds.
